New registry tracks Real-World safety of PFIC drug odevixibat
NCT ID NCT07588880
First seen May 19, 2026 · Last updated May 19, 2026
Summary
This study follows up to 20 people with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their regular care in China. The goal is to see how safe and effective the drug is over the long term, including tracking side effects and whether patients need surgery or a liver transplant. PFIC is a rare genetic liver disease that causes severe itching and bile buildup.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University Endocrinology and Metabolism
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.